Cargando…

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

BACKGROUND: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezeife, Doreen A., Spackman, Eldon, Juergens, Rosalyn A., Laskin, Janessa J., Agulnik, Jason S., Hao, Desiree, Laurie, Scott A., Law, Jennifer H., Le, Lisa W., Kiedrowski, Lesli A., Melosky, Barbara, Shepherd, Frances A., Cohen, Victor, Wheatley-Price, Paul, Vandermeer, Rachel, Li, Janice J., Fernandes, Roxanne, Shokoohi, Aria, Lanman, Richard B., Leighl, Natasha B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340413/ https://www.ncbi.nlm.nih.gov/pubmed/35923926 http://dx.doi.org/10.1177/17588359221112696

Ejemplares similares

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Melosky, Barbara, et al.
Publicado: (2021)

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System
por: Makarem, Maisam, et al.
Publicado: (2021)

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
por: Denault, Marie-Hélène, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
por: Li, Kelly, et al.
Publicado: (2023)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
por: Jacob, Saya L., et al.
Publicado: (2020)

Abstracts of the 2022 Canadian Association of Medical Oncologists Annual Scientific Meeting †
por: Ezeife, Doreen, et al.
Publicado: (2022)

Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study
por: Hilzenrat, Roy Avraham, et al.
Publicado: (2022)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
por: Coschi, Courtney H., et al.
Publicado: (2021)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
por: Patel, Yuti P., et al.
Publicado: (2021)

Ensuring equitable access to cancer care for Black patients in Canada
por: Ezeife, Doreen A., et al.
Publicado: (2022)

Un accès équitable aux soins contre le cancer pour les personnes noires au Canada
por: Ezeife, Doreen A., et al.
Publicado: (2023)

Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis
por: Iragorri, Nicolas, et al.
Publicado: (2018)

Observational evidence in support of screening for depression during pregnancy and the postpartum period
por: Premji, Shainur, et al.
Publicado: (2022)

Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report
por: Yeung, Vincent, et al.
Publicado: (2022)

Knowledge, attitudes, and values among physicians working with clinical genomics: a survey of medical oncologists
por: Chow-White, Peter, et al.
Publicado: (2017)

Locally Advanced Cutaneous Squamous Cell Carcinoma: Two Case Reports of Dramatic Responses to Sequential Cisplatin, Docetaxel and Radiotherapy
por: Dennis, Kristopher E., et al.
Publicado: (2011)

The cost-effectiveness of schistosomiasis screening and treatment among recently resettled refugees to Canada: an economic evaluation
por: Webb, John A., et al.
Publicado: (2021)

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
por: Pugh, Trevor J, et al.
Publicado: (2007)

A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy
por: Geller, Georgia, et al.
Publicado: (2017)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
por: Piccioni, David E, et al.
Publicado: (2019)

Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire
por: Febbraro, Michela, et al.
Publicado: (2023)

Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations
por: Kurzrock, Razelle, et al.
Publicado: (2022)

Impact of Oncology Drug Review Times on Public Funding Recommendations
por: Hussain, Marya, et al.
Publicado: (2023)

Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure
por: Walker, Simon, et al.
Publicado: (2017)

Imaging Biomarkers in Immunotherapy
por: Juergens, Rosalyn A., et al.
Publicado: (2016)

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition
por: Chan, Sze Wah Samuel, et al.
Publicado: (2023)

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
por: Ionescu, Diana N., et al.
Publicado: (2022)

Cost analysis of COVID-19 test result notification using an automated messaging system compared to a staff caller practice in Alberta
por: Loitz, Christina C., et al.
Publicado: (2023)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

The effect of prior cancer on non‐small cell lung cancer trial eligibility
por: Herman, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t2kubug3vn0p2d8gcvok56cpf8